Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Castle Biosciences (CSTL)
NASDAQ:CSTL
Holding CSTL?
Track your performance easily
Earnings Data
Report Date
Mar 04, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
<$0.01Last Year’s EPS
-$0.1Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 04, 2024
|% Change Since: -21.17%
|Next Earnings Date:Mar 04, 2025
Earnings Call Sentiment|Positive
Castle Biosciences reported strong financial performance with significant revenue and test volume growth across its portfolio. The company achieved positive cash flow and raised its revenue guidance for 2024. However, challenges regarding reimbursement, potential impact from recent hurricanes, and ongoing efforts to secure coverage for certain tests were noted.Company Guidance
During Castle Biosciences' Q3 2024 earnings call, the company provided updated revenue guidance, citing strong performance with a 39% increase in revenue and a 41% rise in total test report volume over Q3 2023. The company raised its full-year 2024 revenue guidance to a range of $320 million to $330 million, reflecting a year-over-year growth of 45% to 50%, up from the previous guidance of $275 million to $300 million. Key metrics included 9,367 DecisionDx-Melanoma test reports and 4,195 DecisionDx-SCC test reports in Q3 2024, indicating respective growths of 9% and 49% compared to the same period in 2023. Additionally, the company highlighted the delivery of 6,073 TissueCypher test reports, marking a 115% year-over-year increase. Castle Biosciences also reported a net income of $2.3 million, compared to a net loss of $6.9 million in Q3 2023, and adjusted EBITDA of $21.6 million, up from $6.6 million in the previous year. The company emphasized its strategic focus on long-term growth and continued investment in its innovative test portfolio.Strong Revenue and Test Volume Growth
Castle Biosciences reported a 39% increase in revenue and a 41% growth in total test report volume over Q3 2023. The revenue guidance for 2024 was raised to between $320 million and $330 million, reflecting a year-over-year growth of 45% to 50%.
DecisionDx-Melanoma and DecisionDx-SCC Performance
DecisionDx-Melanoma delivered 9,367 test reports with a 9% year-over-year increase, and DecisionDx-SCC saw a 49% increase in test report volume compared to the same period in 2023.
TissueCypher Test Growth
TissueCypher test volumes reached 6,073 reports in Q3 2024, representing a 115% year-over-year growth.
Positive Cash Flow and Earnings
Castle Biosciences achieved positive cash flow and earnings, with a net income of $2.3 million compared to a net loss of $6.9 million in Q3 2023.
Adjusted EBITDA Improvement
Adjusted EBITDA for Q3 2024 was $21.6 million, an improvement of $15.1 million from the comparable period in 2023.
---
CSTL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CSTL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 04, 2024 | $33.64 | $31.15 | -7.40% |
| Aug 05, 2024 | $21.85 | $24.90 | +13.96% |
| May 02, 2024 | $22.84 | $24.33 | +6.52% |
| Feb 28, 2024 | $24.39 | $18.06 | -25.95% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Castle Biosciences (CSTL) report earnings?
Castle Biosciences (CSTL) is schdueled to report earning on Mar 04, 2025, TBA Not Confirmed.
What is Castle Biosciences (CSTL) earnings time?
Castle Biosciences (CSTL) earnings time is at Mar 04, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CSTL EPS forecast?
CSTL EPS forecast for the fiscal quarter 2024 (Q4) is <$0.01.
---